Loading clinical trials...
Loading clinical trials...
Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors
Conditions
Interventions
SAR408701
Docetaxel
Locations
169
United States
Florida Cancer Specialists South Division- Site Number : 8400020
Fort Myers, Florida, United States
Florida Cancer Specialists North Division- Site Number : 8400019
St. Petersburg, Florida, United States
Ca & Hem Center Of W Michigan- Site Number : 8400016
Grand Rapids, Michigan, United States
Roswell Park Cancer Institute Site Number : 8400011
Buffalo, New York, United States
Lankenau Hospital Cancer Center- Site Number : 8400017
Wynnewood, Pennsylvania, United States
Renovatio Clinical- Site Number : 8400032
El Paso, Texas, United States
Start Date
February 6, 2020
Primary Completion Date
September 22, 2023
Completion Date
March 31, 2026
Last Updated
August 5, 2025
NCT07250477
NCT06517953
NCT04563338
NCT04163432
NCT04504071
NCT03469960
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions